Cargando…
Cipaglucosidase Alfa: First Approval
Cipaglucosidase alfa (Pombiliti(™)) is a recombinant human acid α-glucosidase (GAA) product being developed by Amicus Therapeutics along with the enzyme stabilizer miglustat as a two-component therapy for Pompe disease. Pompe disease is a rare, inherited lysosomal disease caused by a deficiency of t...
Autor principal: | Blair, Hannah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184071/ https://www.ncbi.nlm.nih.gov/pubmed/37184753 http://dx.doi.org/10.1007/s40265-023-01886-5 |
Ejemplares similares
-
Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023) -
Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018) -
Ritlecitinib: First Approval
por: Blair, Hannah A.
Publicado: (2023) -
Belumosudil: First Approval
por: Blair, Hannah A.
Publicado: (2021) -
Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)